Century Therapeutics Inc IPSC

$1.46 -0.12 (-7.59%)

Valuation

Market cap
264,370,000
Revenue TTM
$109,160,000
Net income TTM
$-9,580,000
PE ratio
0.00
Forward PE
—
Profit margin
-8.78%
Debt to equity
0.00

Trading

Volume
892,000
Avg volume
669,010
Day's range
$1.44 – $1.57
Shares out
181,075,000
Stochastic %K
34%
Beta
1.67
Analysts
Strong Sell
Price target
$5.12

Price

Company profile

Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308,...

Show more

Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Industry
Biotechnology
Sector
Healthcare
Phone
267 817 5790
Website
https://www.centurytx.com
Address
25 North 38th Street, 11th Floor, Philadelphia, United States

Latest news

Stocktwits

PJB001 Oct 20, 5:29 PM
$IPSC hmmm not moving
0 replies
PJB001 Oct 20, 5:13 PM
$IPSC hoping for 1.8-1.9 towards the end of the day here
1 replies
ajmrtxl Oct 20, 4:42 PM
$IPSC 's latest squeeze play
0 replies
GlobalTradersAcademy Oct 13, 1:14 PM
$IPSC longest days to cover on my entire board ⏳ century therapeutics would take 50.9 days for shorts to cover at normal volume. 16.1% of the float short proprietary data from our GTA terminal
0 replies
cta7978 Oct 7, 12:49 AM
$IPSC this week. Breakthrough T1D Clinical & Research Congress in Philly Oct 9–11. Century’s oral is Friday Oct 9, 3:50–4:50 PM ET (Hall 1): CNTY-813 scalable Allo-Evasion 5.0 islet manufacturing.
0 replies
cta7978 Oct 6, 6:16 PM
$IPSC Jan gap filled. Up we go!
0 replies
BriOnH Oct 3, 4:03 PM
$SANA I initiated a stake in $IPSC yesterday, and will be DCA for the next month into it. Their 29 day manufacturing and cold storage for transport has piqued my interest enough to invest. I am also very concerned right now they beat Sana to the punch of the first person cured, BUT fact is they carry more risk with it even working in human. My T1D Investments according to size right now: 1)$SANA - by far the largest, and plan to add more as data progresses. 2)$ELDN - Decent chunk. Tego is the ultimate back up, and I see it as a very important gap filler between HIP islets to kidneys, to livers, to lungs, to hearts, and anything else that is going to take time to develop over the next 2-3 decades. Current immunosuppression, Tacrolimus, is toxic and the side effects suck. God forbid with my very progressed CKD, I also may need tego for a kidney someday. I pray not though. 3)$IPSC Micro 1-2% of $ at most. F!!! I maybe picked the wrong horse play as a 50 yr T1D science man. GLA
3 replies
None_ Oct 2, 11:12 PM
$IPSC https://www.globenewswire.com/news-release/2026/10/02/3373783/0/en/century-therapeutics-cnty-813-demonstrates-continued-advancement-toward-the-clinic-via-nonclinical-data-presented-at-easd-2026.html
0 replies